<DOC>
	<DOCNO>NCT02040480</DOCNO>
	<brief_summary>This study conduct measure relative bioavailability original gelatin capsule formulation new formulation , immediate release ( IR ) tablet Afuresertib ( GSK2110183 ) . The study compose Screening , Treatment , Follow-up Periods . A subject 's total time involve study approximately 9 week . The study enroll approximately 18 healthy volunteer .</brief_summary>
	<brief_title>Bioavailability Food Effect Study Gelatin Formulation Immediate Release Tablet Formulation Afuresertib</brief_title>
	<detailed_description />
	<criteria>Provided sign write informed consent Healthy Male female 18 40 year age inclusive , time informed consent obtain . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) &gt; =18 &lt; = 32 kg/meter square ( m^2 ) . A female subject eligible participate ( A ) Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy postmenopausal define 12 month spontaneous amenorrhea ( B ) Childbearing potential negative pregnancy test determine serum human chorionic gonadotropin ( hCG ) test Screening prior dosing , AND : agrees use one acceptable contraception method Male subject female partner childbearing potential must agree use one contraception method . Alanine aminotransferase , alkaline phosphatase bilirubin &lt; =1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single average QT interval correct ( QTc ) value triplicate ECGs obtain brief recording period : QTcB &lt; 450 millisecond ( msec ) ; QTcB &lt; 480 msec subject Bundle Branch Block . Able swallow retain orally administer study treatment clinically significant gastrointestinal ( GI ) abnormality may alter absorption malabsorption syndrome major resection stomach and/or bowel . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History gastroesophageal reflux disease , dyspepsia , peptic ulcer disease , gastrointestinal ( GI ) bleeding , GI surgery could affect motility . History atrial arrhythmias History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 10 gram ( g ) alcohol : 270 mL full strength beer ( 4.8 % ) , 375 mL mid strength beer ( 3.5 % ) , 470 mL light beer ( 2.7 % ) , 250 mL premix full strength spirit ( 5 % ) , 100mL wine ( 13.5 % ) 30 mL spirit ( 40 % ) . History sensitivity study medication , component thereof history drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month Screening . Smoking history regular use tobacco nicotinecontaining product within 6 month prior screen . A positive drug/alcohol screen Screening upon checkin clinic Day 1 Dosing Period . A positive test human immuno virus ( HIV ) antibody . Pregnant female determine positive serum hCG test Screening prior dosing . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Any serious and/or unstable preexist medical , psychiatric disorder condition could interfere subject 's safety , obtain informed consent compliance study procedure . Any prohibited medication recent consumption citrus product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>food effect</keyword>
	<keyword>formulation</keyword>
	<keyword>GSK2110183</keyword>
	<keyword>afuresertib</keyword>
	<keyword>AKT inhibitor</keyword>
</DOC>